SCHEMBL2844945

SCHEMBL2844945

Cc1cc(=O)[nH]nc1-c1ccc(O)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 2/20 0.56
PDE3A Q14432 2/20 0.56
PDGFRB P09619 3/20 0.52
CDK8 P49336 3/20 0.52
NTRK3 Q16288 3/20 0.52
NTRK2 Q16620 3/20 0.52
AURKB Q96GD4 2/20 0.52
MET P08581 1/20 0.52
ROCK1 Q13464 1/20 0.52
CLK4 Q9HAZ1 1/20 0.52
MAPK1 P28482 2/20 0.51
MAP2K4 P45985 2/20 0.51
MAPKAPK2 P49137 2/20 0.51
MAPK6 Q16659 2/20 0.51
MAPKAPK3 Q16644 1/20 0.51
MAPKAPK5 Q8IW41 1/20 0.51
PDPK1 O15530 1/20 0.49
HSP90AB1 P08238 1/20 0.49
GPR119 Q8TDV5 3/20 0.48
FGFR1 P11362 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10353678 0.91 PDE3B (0.63) PDE3BPDE3APDGFRBCDK8NTRK3
SCHEMBL8481283 0.83 PDGFRB (0.59) PDE3BPDE3APDGFRBCDK8NTRK3
SCHEMBL11396639 0.83 HPGD (0.60) PDE3BPDE3APDGFRBCDK8NTRK3
SCHEMBL11632009 0.83 PDE3B (0.56) PDE3BPDE3APDGFRBCDK8NTRK3
SCHEMBL934680 0.83 PDE3B (0.56) PDE3BPDE3APDGFRBCDK8NTRK3
SCHEMBL11474002 0.83 PDE3B (0.56) PDE3BPDE3APDGFRBCDK8NTRK3
SCHEMBL8898020 0.82 HPGD (0.64) PDE3BPDE3APDGFRBCDK8NTRK3
SCHEMBL11393582 0.81 PDE3B (0.55) PDE3BPDE3APDGFRBCDK8NTRK3
SCHEMBL11391374 0.81 PDE3B (0.55) PDE3BPDE3APDGFRBCDK8NTRK3
SCHEMBL11401082 0.81 PDGFRB (0.57) PDE3BPDE3APDGFRBCDK8NTRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160335-A1 PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT KYORIN PHARMACEUTICAL CO., LTD. 2010-06-24 US disclosed
US-20100160335-A1 PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT KYORIN PHARMACEUTICAL CO., LTD. 2010-06-24 US disclosed
US-20100160335-A1 PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT KYORIN PHARMACEUTICAL CO., LTD. 2010-06-24 US disclosed
US-20100130738-A1 PYRAZOLONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT KYORIN PHARMACEUTICAL CO., LTD. (JP) 2010-05-27 US disclosed
US-20100130738-A1 PYRAZOLONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT KYORIN PHARMACEUTICAL CO., LTD. (JP) 2010-05-27 US disclosed
US-20100130738-A1 PYRAZOLONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT KYORIN PHARMACEUTICAL CO., LTD. (JP) 2010-05-27 US disclosed
EP-2168959-A1 PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT Kyorin Pharmaceutical Co., Ltd. (JP) 2010-03-31 EP disclosed
EP-2168960-A1 PYRAZOLONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT Kyorin Pharmaceutical Co., Ltd. (JP) 2010-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130738-A1 PYRAZOLONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT PDE3A, PDE3B, PDE2A PDE3B 2/4885PDE3A 1/4885PDGFRB 210/4885
US-20100160335-A1 PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT PDE3A, PDE5A, PDE2A PDE3B 4/4885PDE3A 1/4885PDGFRB 181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.